Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

Lipocine Shares Jump 30% After Health Canada Approves TLANDO Testosterone Therapy

Lipocine shares surged 30% after Health Canada approved TLANDO, expanding the oral testosterone therapy’s availability into Canada.

Oct 8, 2026
Pharmaceutical

ArriVent BioPharma Plunges 47% After Phase III Lung Cancer Trial Miss

ArriVent’s $AVBP stock fell 46.98% after its FURVENT Phase III trial missed its primary endpoint, cutting market value to about $744 million…

Oct 8, 2026
Pharmaceutical

Viatris’ $36.50-a-Share Pacira Deal Signals Fresh Consolidation in Specialty Pharma

Viatris’ all-cash Pacira acquisition highlights continued US pharmaceutical consolidation and puts specialty-pharma valuations under the mic…

Oct 8, 2026
Pharmaceutical

SeaStar Medical’s FDA Breakthrough Designation Puts $ICU on the Investor Watchlist

SeaStar Medical’s FDA Breakthrough Device designation for its sepsis-therapy device could sharpen investor attention, but it is not an appro…

Oct 7, 2026
Pharmaceutical

Vaxcyte Stock Jumps 30.7% After Positive VAX-31 Pneumococcal Vaccine Data

Vaxcyte shares surged 30.70% after positive Phase 2 data for VAX-31, highlighting the volatility of clinical-stage biotech catalysts.

Oct 7, 2026
Pharmaceutical

Amgen Price Target Raised to $380 as Sjögren’s Trial Strengthens Pipeline Case

Truist raised Amgen’s target to $380 after positive Phase 3 dazodalibep results strengthened the company’s pipeline narrative.

Oct 7, 2026
Pharmaceutical

BridgeBio Maintains Buy Rating After Cardiac Data From Phase 3 FORTIFY Study

Canaccord reiterated its Buy rating on BridgeBio Pharma after exploratory cardiac data from the Phase 3 FORTIFY study of BBP-418.

Oct 7, 2026
Pharmaceutical

AbbVie Adds Two FDA Breakthrough Designations as Temab-A Builds Pipeline Momentum

AbbVie’s Temab-A earned two FDA breakthrough designations, adding an oncology catalyst alongside JUVMO approval and broadening its post-Humi…

Oct 7, 2026
Pharmaceutical

Lipocine Stock Jumps 30% on Health Canada Approval for TLANDO

LPCN’s 30% jump adds regulatory, commercial and clinical catalysts to a biotech trading setup focused on potential follow-through volatility…

Oct 7, 2026
Pharmaceutical

Vaxcyte Stock Jumps 30.7% on Positive VAX-31 Pneumococcal Vaccine Data

Vaxcyte’s $PCVX stock jumped 30.70% after positive VAX-31 data, putting vaccine developers back in the spotlight ahead of regulatory milesto…

Oct 6, 2026
Pharmaceutical

ArriVent BioPharma Stock Plunges 63% After Lung Cancer Drug Misses Phase 3 Endpoint

ArriVent BioPharma shares fell 63% after its Phase 3 FURVENT trial missed its primary endpoint, highlighting binary biotech risk.

Oct 6, 2026
Pharmaceutical

Option Care Health Surges 34% as McKesson and CD&R Agree to $5.8 Billion Takeover

Option Care Health jumped 34% after McKesson and CD&R agreed to a $5.8 billion takeover, highlighting ongoing US healthcare consolidation.

Oct 6, 2026